Literature DB >> 2886167

D2-dopamine receptor-mediated inhibition of intracellular Ca2+ mobilization and release of acetylcholine from guinea-pig neostriatal slices.

H Fujiwara, N Kato, H Shuntoh, C Tanaka.   

Abstract

The effect of dopamine receptor activation on electrically- or high K+ (30 mM)-evoked neurotransmitter release and rise in intracellular Ca2+ concentration was investigated using slices of guinea-pig neostriatum. A specific D2-dopamine receptor agonist, LY-171555 (a laevorotatory enantiomer of LY-141865: N-propyl tricyclic pyrazole) at 10(-6) M inhibited electrical stimulation- and high K+-evoked release of [3H]-acetylcholine ([3H]-ACh) to 47.7 +/- 6.0% and 54.1 +/- 5.0% of control, respectively. The maximal inhibition by LY-171555 at 10(-5) M was 54.8 +/- 5.1% reduction of the control. The half-maximal effective concentration (EC50) of LY-171555 for the inhibition of [3H]-ACh release was 2.3 X 10(-7) M. A specific D2-dopamine receptor antagonist, (-)-sulpiride (10(-7) M) reversed the inhibition of [3H]-ACh release induced by LY-171555. A specific D1-dopamine receptor agonist, SK&F 38393 (2,3,4,5-tetrahydro-7,8-dihydroxy-1-phenyl-1H-benzazepine) (10(-5) M) had no effect on the release of [3H]-ACh. LY-171555 (10(-6) M) also inhibited the high K+-evoked endogenous glutamate release, by 47% of control. This inhibitory effect was reversed by (-)-sulpiride (10(-7) M). We used a fluorescent, highly selective Ca2+ indicator, 'quin 2' to measure intracellular free Ca2+ concentrations ([Ca2+]i). Electrical stimulation of slices preloaded with quin 2 led to an elevation of relative fluorescence intensity and this response was reduced by the removal of Ca2+ from the bathing medium. These results indicate that the enhanced elevation in fluorescence intensity in the quin 2-loaded slices reflects the increase of intracellular free Ca2+ concentration, [Ca2+]i. The mixed D1- and D2-receptor agonist, apomorphine and LY-171555 inhibited the increase of [Ca2+]i induced by electrical stimulation or high K+ medium, in a concentration-dependent manner, while SK&F 38393 did not affect the increase of [Ca2+]i. The maximal inhibitory effect of LY-171555 at 3 X 10(-5) M was 35 +/- 3% reduction in control values. The inhibitory effect of LY-171555 was antagonized by (-)-sulpiride (10(-7) M). There was a high correlation (r = 0.997, P less than 0.05) between the D 2-receptor-mediated inhibition of the stimulated rise of [Ca2+]i and [3H]-ACh release. When the slices were superfused with the Ca2+-free medium containing EGTA (10(-4) M) for 5 min, the rise in [Ca2+]i was markedly suppressed to 18.0% of control by LY-171555 (10(-6) M). These data indicate that activation of the D2-dopamine receptor suppresses the elevation of [Ca2+]i induced by depolarizing stimuli. This may be due to inhibition of mobilization of Ca2+ from the intracellullar store. We propose that the D2-receptor-mediated inhibition of transmitter release is probably due to a reduction in intracellular Ca2+ mobilization.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2886167      PMCID: PMC1853530          DOI: 10.1111/j.1476-5381.1987.tb10283.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  30 in total

1.  Effect of dopamine agonists and neuroleptic agents on striatal acetylcholine transmission in the rat: evidence against dopamine receptor multiplicity.

Authors:  B Scatton
Journal:  J Pharmacol Exp Ther       Date:  1982-01       Impact factor: 4.030

2.  T-cell mitogens cause early changes in cytoplasmic free Ca2+ and membrane potential in lymphocytes.

Authors:  R Y Tsien; T Pozzan; T J Rink
Journal:  Nature       Date:  1982-01-07       Impact factor: 49.962

3.  Dopamine inhibition of action potentials in a prolactin secreting cell line is modulated by oestrogen.

Authors:  B Dufy; J D Vincent; H Fleury; P Du Pasquier; D Gourdji; A Tixier-Vidal
Journal:  Nature       Date:  1979 Dec 20-27       Impact factor: 49.962

4.  Effect of hippocampus extirpation in the rat on glutamate levels in target structures of hippocampal efferents.

Authors:  C Nitsch; J K Kim; C Shimada; Y Okada
Journal:  Neurosci Lett       Date:  1979-03       Impact factor: 3.046

5.  Calcium transients recorded with arsenazo III in the presynaptic terminal of the squid giant synapse.

Authors:  R Miledi; I Parker
Journal:  Proc R Soc Lond B Biol Sci       Date:  1981-05-22

6.  Dopamine inhibits 32P incorporation into phosphatidylinositol in the anterior pituitary gland of the rat.

Authors:  P L Canonico; C A Valdenegro; R M Macleod
Journal:  Endocrinology       Date:  1982-07       Impact factor: 4.736

7.  Calcium homeostasis in intact lymphocytes: cytoplasmic free calcium monitored with a new, intracellularly trapped fluorescent indicator.

Authors:  R Y Tsien; T Pozzan; T J Rink
Journal:  J Cell Biol       Date:  1982-08       Impact factor: 10.539

8.  Stereoselectivity of presynaptic autoreceptors modulating dopamine release.

Authors:  S Arbilla; S Z Langer
Journal:  Eur J Pharmacol       Date:  1981-12-17       Impact factor: 4.432

9.  Specific calcium-dependent release of endogenous glutamate from rat striatum is reduced by destruction of the cortico-striatal tract.

Authors:  G J Rowlands; P J Roberts
Journal:  Exp Brain Res       Date:  1980       Impact factor: 1.972

10.  Site(s) and ionic basis of alpha-autoinhibition and facilitation of "3H'noradrenaline secretion in guinea-pig vas deferens.

Authors:  P Alberts; T Bartfai; L Stjärne
Journal:  J Physiol       Date:  1981-03       Impact factor: 5.182

View more
  2 in total

Review 1.  Striatal dopamine in motor activation and reward-mediated learning: steps towards a unifying model.

Authors:  J Wickens
Journal:  J Neural Transm Gen Sect       Date:  1990

2.  Investigations of the roles of dihydropyridine and omega-conotoxin-sensitive calcium channels in mediating depolarisation-evoked endogenous dopamine release from striatal slices.

Authors:  H Herdon; S R Nahorski
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-07       Impact factor: 3.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.